Comparison of tacrolimus with neoral as primary immunosuppression in hepatitis C patients after liver transplantation.
Zervos
X A
XA
Weppler
D
D
Fragulidis
G P
GP
Torres
M B
MB
Nery
J R
JR
Khan
M F
MF
Pinna
A D
AD
Kato
T
T
Miller
J
J
Reddy
K R
KR
Tzakis
A G
AG
D000328:Adult; D000368:Aged; D016572:Cyclosporine / Q000009:adverse effects / Q000627:therapeutic use*; D005260:Female; D006084:Graft Rejection / Q000453:epidemiology; D016174:Hepacivirus / Q000302:isolation & purification; D006526:Hepatitis C / Q000503:physiopathology / Q000601:surgery* / Q000821:virology; D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects / Q000627:therapeutic use*; D015994:Incidence; D008113:Liver Neoplasms / Q000276:immunology*; D008297:Male; D008775:Methylprednisolone / Q000627:therapeutic use; D008875:Middle Aged; D012367:RNA, Viral / Q000032:analysis; D012008:Recurrence; D016559:Tacrolimus / Q000009:adverse effects / Q000627:therapeutic use*
D007166:Immunosuppressive Agents; D012367:RNA, Viral; D016572:Cyclosporine; D016559:Tacrolimus; D008775:Methylprednisolone